TCTR20171106003.

Study name	High‐flow nasal oxygen for prevention of intubation in acute non‐hypercapnic hypoxemic respiratory failure in immunocompromised patients, a randomized trial
Methods	RCT, parallel‐group design
Participants	Estimated number of participants: 74 Setting: Thailand Inclusion criteria: immunocompromised patients; solid or haematologic malignancy; received immunosuppressive drug or steroid at a dose > 20 mg/day of prednisolone for > 30 days; HIV infection; require nasal low‐flow oxygen of 4 L/min to maintain PaO2 above 60 mmHg or SpO2> 90% for > 1 hour; age ≥ 18 years Exclusion criteria: PaCO2> 45 mmHg; post‐extubation respiratory failure (respiratory failure within 48 hr after extubation); life‐threatening AHRF requiring immediate invasive MV; shock; active pulmonary tuberculosis; contraindications to NIV; do‐not‐intubate order; patients refused to participate in the study
Interventions	Intervention group (HFNC) Control group (NIV)
Outcomes	All outcomes measured: required intubation and invasive mechanical ventilation within 48 hrs; 30‐day mortality rate Outcomes relevant to this review: required intubation and invasive mechanical ventilation within 48 hrs; 30‐day mortality rate
Starting date	7th August 2017
Contact information	Juthamas Inchai, juinchai@gmail.com
Notes